Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Abdominal discomfort

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44256   clinical trials with a EudraCT protocol, of which   7344   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    102 result(s) found for: Abdominal discomfort. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2016-002110-42 Sponsor Protocol Number: PHRCIR2015DAPOIGNY Start Date*: 2017-10-18
    Sponsor Name:CHU CLERMONT-FERRAND
    Full Title: Evaluation of the effectiveness and safety of ethosuximide in the treatment of abdominal pain associated with irritable bowel syndrome
    Medical condition: abdominal pain related to irritable bowel syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000436-24 Sponsor Protocol Number: AGI006-001 Start Date*: 2005-04-08
    Sponsor Name:AGI Therapeutics Limtied
    Full Title: A randomised, double-blind, placebo-controlled study of AGI 006 in the treatment of functional dyspepsia.
    Medical condition: Functional (Non-ulcer) Dyspepsia (FD; NUD)
    Disease: Version SOC Term Classification Code Term Level
    6.0 10013946 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000448-26 Sponsor Protocol Number: ITOFD04-03 Start Date*: 2005-01-05
    Sponsor Name:Axcan Pharma Inc. (Axcan Pharma International BV is subsidiary of Axcan Pharma Inc.)
    Full Title: A multicentre, randomized, double-blind, placebo-controlled study of the efficacy and safety of Itopride HCl in patients suffering from functional dyspepsia
    Medical condition: Treatment of abdominal symptoms in patients with functional dyspepsia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002762-38 Sponsor Protocol Number: Clin-AGI001-001 Start Date*: 2005-04-13
    Sponsor Name:AGI Therapeutics Limited
    Full Title: A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of functional dyspepsia
    Medical condition: Functional (Non-ulcer) Dyspepsia
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001394 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005467-16 Sponsor Protocol Number: 55995 Start Date*: 2016-06-01
    Sponsor Name:Maastricht University
    Full Title: Peppermint oil for the treatment of Irritable Bowel Syndrome: optimizing therapeutic strategies using targeted delivery
    Medical condition: Irritable Bowel Syndrome
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-001282-34 Sponsor Protocol Number: ITOFD04-01 Start Date*: 2005-07-30
    Sponsor Name:AXCAN PHARMA Inc.
    Full Title: A multicentre, randomized, double-blind, placebo-controlled study of the efficacy and safety of itopride HCl in patients suffering from functional dyspepsia
    Medical condition: Treatment of abdominal symptoms in patients with functional dyspepsia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003690-65 Sponsor Protocol Number: 78304 Start Date*: 2021-11-10
    Sponsor Name:St Antonius Hospital
    Full Title: Peppermint Oil for the treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT study
    Medical condition: Irritable Bowel syndrome Functional Abdominal Pain Not otherwise specified
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001950-18 Sponsor Protocol Number: AST014 Start Date*: 2007-07-23
    Sponsor Name:Ocera Therapeutics, Inc.
    Full Title: A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF AST-120 IN PATIENTS WITH NON-CONSTIPATING IRRITABLE BOWEL SYNDROME
    Medical condition: Irritable bowel syndrome (IBS) is a chronic functional bowel disorder characterized by abdominal pain or discomfort and laterations in bowel habits. IBS is one of the most frequent conditions physi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020906-14 Sponsor Protocol Number: 50591903 Start Date*: 2011-03-31
    Sponsor Name:MUMC
    Full Title: Randomized controlled trial of escitalopram versus placebo for patients with irritable bowel syndrome and panic disorder.
    Medical condition: IBS and panic disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004230-14 Sponsor Protocol Number: Clin-AGI001-002 Start Date*: 2004-12-22
    Sponsor Name:AGI Therapeutics Limited
    Full Title: A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of irritable bowel syndrome.
    Medical condition: Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    6.0 10023003 PT
    Population Age: Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012393-12 Sponsor Protocol Number: IPR-MET-7 Start Date*: 2009-09-11
    Sponsor Name:Laboratoires IPRAD
    Full Title: Essai comparatif, multicentrique, prospectif, randomisé, en double insu, d’efficacité et de tolérance de Météoxane® versus placebo dans la poussée douloureuse du syndrome de l'intestin irritable
    Medical condition: Irritable bowel syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004308-19 Sponsor Protocol Number: ITOFD04-04 Start Date*: 2005-02-23
    Sponsor Name:AXCAN PHARMA Inc.
    Full Title: A multicentre, open-label study to evaluate the long-term safety and efficacy of itopride HCl in patients suffering from functional dyspepsia
    Medical condition: Treatment of abdominal symptoms in patients with functional dyspepsia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019343-20 Sponsor Protocol Number: 654-002 Start Date*: 2010-10-15
    Sponsor Name:LOTUS PHARMACEUTICAL CO., LTD.
    Full Title: A DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP STUDY TO COMPARE THE SAFETY AND EFFICACY OF TWO DOSE LEVELS OF OMS210 WITH PLACEBO IN THE TREATMENT OF PATIENTS WITH DIARRHOEA PREDOMINANT IRRITABLE BOWEL...
    Medical condition: Diarrhoea predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048571 Irritable bowel syndrome aggravated LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018300-85 Sponsor Protocol Number: NAK-04 Start Date*: 2010-07-23
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) SE (Completed) IT (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-004702-14 Sponsor Protocol Number: 530079.01.302 Start Date*: 2016-04-01
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Efficacy and Tolerability of Menthacarin in Patients (≥ 18 years old) suffering from symptoms of Irritable Bowel Syndrome (IBS)
    Medical condition: Symptoms of Irritable Bowel Syndrome (IBS) characterized by recurrent abdominal pain, abdominal discomfort, abdominal cramping, abdominal fullness, abdominal bloating or flatulence usually accompan...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003880-61 Sponsor Protocol Number: 060-CL-305 Start Date*: 2005-02-08
    Sponsor Name:Yamanouchi Europe B.V.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE POTENTIAL EFFICACY, SAFETY AND TOLERABILITY OF DIFFERENT ORAL DOSES OF YM060 IN PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE ...
    Medical condition: diarrhea-predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    10023003
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-000895-14 Sponsor Protocol Number: NAK-07 Start Date*: 2014-01-27
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: A 52-week, double-blind, randomised, placebo-controlled, parallel-group phase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in f...
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D) in female patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    18.0 100000004856 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Prematurely Ended) SE (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000894-56 Sponsor Protocol Number: NAK-06 Start Date*: 2014-02-26
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: A 12-week double-blind, randomised, placebo-controlled, parallel group phase III study, followed by a 4-week randomised withdrawal period to evaluate the efficacy and safety of oral ibodutant 10 mg...
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D) in female patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    18.0 100000004856 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) IT (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-015728-27 Sponsor Protocol Number: AH-IBS-005 Start Date*: 2009-11-13
    Sponsor Name:Alimentary Health Ltd
    Full Title: A Double Blind, Randomised, placebo-contoled Trial to establish teh safety and efficacy of a probiotic in subjects with Irritable Bowel Syndrome
    Medical condition: Irritable bowel Syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004939-73 Sponsor Protocol Number: LINACLOTIDEPLACEBO Start Date*: 2014-05-13
    Sponsor Name:KULEUVEN
    Full Title: A RANDOMISED, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFECT OF LINACLOTIDE ON COLONIC MOTILITY ASSESSED WITH INTRALUMINAL COLONIC MANOMETRY IN HEALTHY SUBJECTS
    Medical condition: COLONIC MOTILITY WILL BE STUDIED IN HEALTHY SUBJECTS
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA